I'll research CHD (Church & Dwight) before writing the preview. Let me gather recent filings, transcripts, and news.Let me read the most recent transcript (2026Q1) and release, plus check the year-ago Q2 for comparison.Let me get recent stock price action and search for the latest news and analyst expectations.Let me check the latest news and analyst expectations.I now have what I need. Here's the earnings preview.
CHD heads into Q2 as a "beat-and-hold" story: management has guided to a soft-looking quarter on purpose (front-half EPS pressure, back-half recovery), so the real questions are (1) whether underlying organic momentum holds as the Q1 inventory tailwind rolls off, and (2) whether commodity/transportation inflation forces any change to the full-year framework. Expectations are modest, which lowers the bar.
On the May 1 Q1 call, management gave unusually specific Q2 guidance:
| Metric | Q2 2026 Guide | Q2 2025 Actual | Implied YoY |
|---|---|---|---|
| Reported net sales | ~ –1% | $1,506.3M | Decline (portfolio actions) |
| Organic sales | ~ +3% | +0.1% | Big accel. (easy comp) |
| Adjusted gross margin | ~ +50 bps | 45.0% | ~45.5% |
| Adjusted EPS | $0.88 | $0.94 (adj.) | ~ –6% |
Two structural points to keep front of mind: - Reported sales fall entirely because of 2025 portfolio actions. CHD exited Flawless, Spinbrush, the Waterpik showerhead business, and divested the VMS (vitamins) business — collectively ~$400M of revenue and stranded costs the company is lapping/absorbing this year. Organic growth is the number that matters. - First half is designed to be flattish; growth is back-half-weighted. Q1 adj. EPS was +4.4% ($0.95), so a ~–6% Q2 nets to roughly flat H1. This is driven by higher marketing, Touchland amortization/SG&A, and transportation costs hitting before mitigation kicks in.
Street estimates cluster right around the guide: consensus adjusted EPS of roughly $0.89 (vs. the $0.88 guide) on revenue near $1.5B. Note CHD has beaten EPS in most recent quarters (trailing average surprise mid-single digits), so a modest headline beat would not be a surprise — the reaction will hinge on organic sales quality and the full-year outlook, not the penny.
1. Organic sales quality as the Q1 tailwind fades. Q1 organic was a blockbuster +5.0%, but management was explicit that ~2 points came from lapping last year's retail-inventory destocking — a one-time help. Underlying "categories growing ~3%, CHD a bit faster" is the true run-rate, hence the ~3% Q2 guide. Watch: Did categories hold ~3%? Did CHD again grow faster and take share? Management flagged being #1 across all of CPG in total distribution points gained, with resets hitting now (a claimed ~7% TDP lift on a 13-week basis, closer to 10–11% more recently) — that's the durability argument. New products are expected to drive ~half of 2026 organic growth.
2. Gross margin vs. the Middle East / commodity headwind. Management sized incremental oil-derivative and transportation inflation at $25–30M for the full year (surfactants, resin, diesel), on top of ~160 bps already in the plan — bringing inflation to ~200 bps. They plan to offset it with productivity, not pricing (Dierker was emphatic the pressed consumer can't absorb price). Q2 is the quarter where transportation bites before mitigation, hence only +50 bps GM (vs. +130 bps in Q1 and ~+100 bps full-year). Watch for any change in the $25–30M figure and confidence in the productivity offset — this is the swing factor for the year.
3. Does the full-year guide hold, move up, or get trimmed? The framework: organic +3–4%, adjusted EPS +5–8% ($3.71–$3.81 adj.; reported $3.57–$3.67, +18–22%), GM ~+100 bps, CFO ~$1.15B. Despite the Q1 beat, management only reiterated — they did not raise, citing the fluid Middle East situation. After a strong H1 print, the debate is whether they nudge organic toward the high end. A guidance change typically moves CHD more than the quarter itself.
4. Touchland — the growth engine that just decelerated. Q2 2026 is essentially the first full quarter Touchland is in the base (deal closed July 2025). Tracked-channel consumption looked down ~20% in Q1 as it lapped launches and holiday multipacks, but management says all-in consumption (incl. untracked/club/Amazon) was still +12–13%, and reiterated double-digit full-year growth with most advertising/collaborations landing in H2. Watch for hard numbers and integration commentary — Touchland is central to the growth thesis and the SG&A/amortization drag.
5. Brand-level momentum. - THERABREATH: record mouthwash share (+3.5 pts to 24.1%, #2 in category, still <20% of shelf); toothpaste launch off to a strong start (~4.6 rating). - HERO: share leader ~2x the next competitor; Mighty Shield hitting retailer hurdles; three facial cleansers launching mid-2026 (a Q2/Q3 catalyst). - ARM & HAMMER: record laundry share (+4.1% consumption vs. 2.7% category) with lower promotion; litter consumption +6.8%, share +0.4 pt to 24.6%. The value-tier "Baking Soda Fresh" launch is a key 2026 innovation. - Watch the drags: OXICLEAN (lapping a large club distribution loss — trends improving), WATERPIK flossers, and lower Middle East regional sales weighing on International.
This is a quarter engineered to look weak on the headline (flat-to-down EPS, reported sales decline from divestitures) while the underlying franchise stays healthy. The bull case rests on organic sales holding ~3%+ on genuine share/distribution gains (not just the fading inventory tailwind), Touchland re-accelerating, and management defending the +100 bps GM / +5–8% EPS full-year framework despite oil-driven inflation. The bear case is a decelerating top line once the Q1 sugar-high rolls off, combined with any crack in the "offset inflation with productivity, no pricing" plan. After an ~18% YTD run, guidance tone will likely matter more than the reported penny.
Note: figures above are drawn from CHD's Q1 2026 (May 1) release and call, the Q2 2025 comparison release, and current Street estimates. All references to Q2 2026 "results" are guidance/consensus — actuals report July 31.